Hepatitis C

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), a small enveloped RNA virus of the family Flaviviridae. It is spread mainly through contact with infected blood, most often by sharing injection equipment, and it can cause both a short acute illness and a long-term chronic infection. Many people never notice symptoms, and untreated chronic infection can slowly lead to cirrhosis, liver failure and liver cancer. Unlike hepatitis B, for which an effective vaccine exists, there is still no licensed vaccine against hepatitis C, so prevention depends on screening, safer injection practices and harm-reduction services.

The condition matters because it is both common and treatable. Before 2011 the standard therapy was a long course of interferon combined with ribavirin, which cured only a minority of patients and caused severe side effects. The introduction of direct-acting antivirals (DAAs) transformed care: short, well-tolerated oral regimens now cure more than 95% of treated patients. The main obstacle is no longer the drugs themselves but the failure to diagnose and treat people in time, a gap that the World Health Organization tracks as part of its global elimination targets.

This entry covers the virus and its life cycle, the routes and risk groups for infection, the natural history from acute infection to liver cancer, clinical diagnosis and staging, the evolution of treatment from interferon to DAAs, prevention and harm reduction, global epidemiology and policy, immunity and the difficulty of vaccine development, special populations, and the open questions that remain for the coming decade.

Discovery and naming

Hepatitis A and hepatitis B had both been characterised before the hepatitis C agent was found. In the early 1970s, several research groups began to study the relationship between HBV infection in blood donors and the development of post-transfusion hepatitis. The cases that did not fit were distinct: the residual "non-B" form had a shorter incubation period and milder symptoms during the acute phase. Other viral causes, including hepatitis D and cytomegalovirus, were also excluded from this group as the known hepatitis viruses, i.e., hepatitis A virus (HAV), hepatitis B virus (HBV), and delta hepatitis virus (HDV), as well as the hepatitis induced by cytomegalovirus (CMV) or Epstein-Barr virus (EBV). The label "non-A, non-B" therefore described what the disease was not, rather than what caused it.

Attempts to identify the agent relied first on animal experiments. Transmission to chimpanzees, and serial passage in chimpanzees provided evidence that NANBH is due to a transmissible infectious agent or agents. Investigators then used the animals to describe the agent's physical properties. Filtration experiments suggested a particle of about 50 to 80 nM, and loss of infectivity after chloroform exposure pointed to the presence of a lipid envelope. These findings indicated a small enveloped agent. Progress stalled because almost all attempts made so far by various researchers have failed in identification of the causative agent virus because of the poor reproducibility of the reported results. Traditional immunological methods failed for roughly a decade before Michael Houghton et al. applied recently developed molecular screening approaches to identify and clone the virus directly.

The breakthrough came in 1989. Starting from a recombinant expression library derived from infected chimpanzee plasma, the cDNA was expressed in bacteria and the expressed proteins were then screened against serum from NANBH patients to identify reactive clones. The logic rested on the assumption that patients' blood would contain antibodies to the missing virus, and following a comprehensive search, one positive clone was found. That clone pointed to a larger RNA molecule that was found mainly in the samples from patients, and the agent was then named hepatitis C virus. Its genome had been cloned and sequenced by 1989, with the work initially identified by Michael Houghton and his team at Chiron Corporation. The original report is often described as the first virus to be discovered by molecular cloning without direct use of biological or biophysical methods.

Identifying a virus in patients' blood did not by itself prove it caused the disease. Charles Rice later supplied that proof. He engineered an RNA variant of the virus that lacked inactivating mutations, and when this RNA was injected into the liver of chimpanzees, virus was detected in the blood and pathological changes resembling those seen in humans with the chronic disease were observed. A diagnostic antibody test followed, and soon enough, the first diagnostic HCV antibody test was developed, which led to a dramatic decrease in new infections.

The 2020 Nobel Prize in Physiology or Medicine was awarded jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. The prize committee noted that the discovery of the Hepatitis A and B viruses had been critical steps forward, but the majority of blood-borne hepatitis cases remained unexplained. Alter's work had defined a new, distinct form of chronic viral hepatitis.

The letter-based classification was built by exclusion: each newly identified agent removed cases from the unexplained pool. Because the residual category was defined only by what it was not, its scale was hard to measure before a specific agent was known. Sources also differ on when it was first recognised, with one placing it in 1974 and another describing it in the mid-1970s. The almost 15 years between recognition and identification help explain why many chronic infections were long unrecognised.

Virus structure and classification

Hepatitis C virus is the sole recognized member of the genus Hepacivirus in the family Flaviviridae, a group that also includes dengue, yellow fever and West Nile viruses. Its closest relatives are the GB viruses, which are hepaciviruses found in other primates and share a similar genome organisation and replication strategy. HCV is an enveloped particle, roughly 40–70 nm in diameter, in which a nucleocapsid built from the core protein is surrounded by a lipid membrane.

The genome is a single-stranded, positive-sense RNA molecule of about 9.6 kilobases. Its 5′ untranslated region contains a type IV internal ribosome entry site of about 340 nucleotides, which allows translation to begin without a conventional cap-dependent step. The bulk of the genome is one open reading frame that encodes a polyprotein of roughly 3,000 amino acids. Host and viral proteases cleave this precursor into ten mature proteins, arranged in the order core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B. The structural proteins occupy the N-terminal third of the polyprotein, while the non-structural proteins, which form the replication machinery, lie in the C-terminal portion. Among the non-structural proteins, NS4B induces a membranous replication complex on the endoplasmic reticulum, and NS5B, a roughly 68 kDa protein, carries RNA-dependent RNA polymerase activity.

The envelope glycoproteins E1 and E2 form the outer surface of the virion. They can associate as heterodimers, and their sequences are highly variable, which allows the virus to evade antibody responses. The virion also circulates in association with host lipoproteins, a feature that is thought to contribute to its entry into hepatocytes and to make it physically distinct from many other viruses that have been studied.

HCV is classified into genotypes and subtypes according to sequence divergence, with genotypes differing by a larger share of nucleotides than subtypes. The number of recognised genotypes has changed over time. Older schemes described six major genotypes, numbered 1 to 6, while more recent reviews list seven genotypes and describe between roughly 67 and 84 subtypes, depending on the source. Genotypes 1 to 3 are the most widespread worldwide, and their distribution differs by region. Genotype matters clinically because it can influence the expected response to therapy and the choice of regimen, although the advent of pangenotypic drugs has reduced its importance in treatment decisions. Within a single infected person, the genome also exists as a population of closely related variants known as a quasispecies, which contributes to the difficulty of classifying the virus into fixed categories.

Replication and the viral life cycle

HCV is an enveloped virus that infects hepatocytes almost exclusively, and its life cycle runs through entry, translation and replication, assembly, and release. Entry is a stepwise process. The virion first attaches to the cell surface through interactions with glycosaminoglycans and the low-density lipoprotein receptor. It then engages CD81 and scavenger receptor class B type I (SR-BI), and finally uses the tight-junction proteins claudin-1 and occludin, which are needed for the particle to be internalised. Because several receptors act in sequence, the virus depends on the cell's own membrane and junction biology, and this explains why infection is restricted to liver cells in practice.

After uncoating, the single-stranded, positive-sense RNA genome is released into the cytoplasm and translated directly on the endoplasmic reticulum (ER) as one large polyprotein. Host and viral proteases cut this precursor into individual proteins. The non-structural proteins, including NS3, NS4A, NS4B and NS5A, remodel ER-derived membranes into a membranous web, a network of altered vesicles that concentrates the replication machinery and shields double-stranded RNA intermediates from innate sensors. Within this compartment, the RNA-dependent RNA polymerase NS5B first synthesises a complementary negative-strand copy and then produces many new positive-strand genomes from it. Replication is therefore a closed cycle in which both the template and the progeny are made inside membrane structures that the virus has built for itself.

The polymerase has a high error rate. NS5B lacks the 3′-to-5′ proofreading activity found in many other replicases, so mistakes introduced during copying are rarely corrected. On average, a substantial share of newly made genomes carries at least one change, and the infected person therefore harbours a swarm of closely related variants known as a quasispecies. This diversity has two practical consequences. Some variants can evade neutralising antibodies and T-cell responses, which is one reason the immune system struggles to clear chronic infection. Other variants carry substitutions that reduce susceptibility to direct-acting antivirals, so resistance-associated variants can be selected during treatment, especially when drugs are given as monotherapy or with poor adherence.

Assembly and release are tightly linked to hepatocyte lipid metabolism. The core protein coats the genome at or near lipid droplets, which sit close to the ER, while the envelope glycoproteins E1 and E2 mature in the ER membrane. The nascent particle then acquires host apolipoproteins and lipids, and it leaves the cell by using the same secretory pathway that exports very-low-density lipoprotein. The resulting lipoprotein-associated particles are less dense than typical virions and are more infectious than free virions, which helps explain why the virion's lipid composition is closely tied to its ability to enter new cells. Core and non-structural proteins, notably NS5A, also alter lipogenesis and fatty acid oxidation, and this interference is one mechanistic basis for the steatosis frequently seen in chronic infection. The link between viral replication and fat handling therefore goes beyond incidental co-occurrence: the same pathways that the virus uses to package itself are also those that drive fat accumulation in the liver.

Taken together, the stages of the life cycle identify the points that current drugs target. The NS3 protease, the NS5A protein and the NS5B polymerase each perform steps that the virus cannot easily bypass, and their roles in membrane remodelling, RNA synthesis and particle formation shape both the efficiency of replication and the emergence of resistance.

Transmission and risk groups

Hepatitis C is a bloodborne virus, so transmission almost always involves infected blood entering another person's bloodstream. Transmission may be through infected blood products or transfusions as well as contaminated injections in medical settings and among people who inject drugs. Before the late 1980s, transfusion was a major source of infection. Once the first commercial antibody test appeared in 1991, transmission through blood products was effectively halted, and sharing of injecting equipment among people who inject drugs became the major route of transmission in high-income countries.

In many middle- and high-income countries, injection drug use is the leading cause of HCV transmission, via sharing of contaminated needles. The EU picture is similar: injecting drug use currently accounts for 80% of new HCV infections with a known transmission route. The virus spreads through more than needles alone. It can also be transmitted through sharing cookers or spoons, cotton and filters, and water. Because the virus survives in equipment and small amounts of blood, even brief sharing carries a risk.

In low- and middle-income settings, the routes are different. Unsafe medical practice remains a central source, including reused injection equipment and blood that has not been adequately screened. For children in resource-limited settings, most cases of hepatitis C can be traced to transfusion of inadequately-screened blood products and/or parenteral transmission.

Sexual transmission is much less efficient than blood-borne spread. In contrast to hepatitis B, the risk of sexual transmission of HCV has always been considered low. In one study of HIV-negative couples in which one partner had HCV, the maximum incidence rate of HCV transmission by sex was 0.07% per year, or one infection per 190,000 sexual contacts, with no association with specific sexual practices. Risk is higher where blood is involved. Practices such as anal or rough vaginal sex that cause bleeding can raise the chance of transmission.

Among men who have sex with men (MSM), the picture is more complicated. HIV-positive MSM are at highest risk, with seroprevalence up to 9% observed in this group. In a study of HIV-infected MSM, most HCV infections without a history of rectal trauma or bleeding or shared injection equipment were caused by a single virus, which suggests that intra-rectal exposure to semen during condomless receptive anal intercourse is likely sufficient for HCV transmission. Risk also depends on the partner network: risk factors included unprotected receptive anal intercourse with multiple partners, HIV infection, and lower CD4 T-cell count among HIV-infected men. Transmission has also been documented in HIV-negative MSM who take pre-exposure prophylaxis, and the reinfection risk following clearance is about 10 times the risk of primary infection.

Mother-to-child transmission is less frequent than many other routes but is a significant source of childhood infection. Estimates for the rate of vertical transmission range from 3% to 10%. In one UK and Irish cohort, the vertical transmission rate was 6.7% overall, and 3.8 times higher in HIV coinfected than in HIV-negative women after adjustment for other factors. The risk is also highest among women with a high viral load at delivery. Breastfeeding is generally not considered a meaningful route. Maternal HCV infection is not a contraindication to breastfeeding under CDC and American Academy of Pediatrics guidance. One European cohort did find that among HIV co-infected women, those who breastfed were about four times more likely to infect their children than those who did not, so the advice applies most clearly to women without HIV coinfection.

Acute and chronic infection

Acute hepatitis C is usually quiet. Most people who become infected have little or no illness in the early weeks, and the timing of infection is hard to pin down, which makes the acute phase difficult to study. Acute HCV infection is usually asymptomatic and is only very rarely associated with life-threatening disease. Accurate studies of the time course for clearance of acute hepatitis C are difficult to carry out because of the silent onset of the acute disease. When symptoms do occur, they include fever, fatigue, nausea, abdominal pain, dark urine, jaundice and joint pain. Many infections are therefore identified only when a routine blood test shows raised liver enzymes, or much later.

Published estimates of spontaneous clearance differ. The WHO European Region's figures put the share of people who clear the virus within six months at about 15–45%, while a clinical overview gives an average of about 30% and another study cites approximately 20–25%. The gaps largely reflect differences in cohort design, in how acute cases were found, and in how clearance was defined. Clearance is driven by the immune system: HCV-specific CD4+ and CD8+ T cells and natural killer cells can suppress the virus, and natural killer cells act partly by releasing interferon gamma. The NK cells can inhibit virus replication in infected hepatocytes by direct cytotoxicity and the production of inflammatory cytokines. Host factors also matter. Variants in the IL28B gene and an HLA class II allele are associated with spontaneous resolution. In one cohort, clearance was more frequent in people under 50, and older age at time of primary infection was a significant predictor of virus clearance in another analysis. Alcohol use appears to influence the outcome, and HIV co-infection lowers the chance of clearance, possibly because impaired T- and NK-cell activity makes chronic infection more likely.

Those who do not clear the virus develop chronic infection, which accounts for the majority of cases; the remaining 55–85% will develop chronic infection. Public-health surveillance uses a stricter operational definition, classing a case as chronic when viral RNA or core antigen is detected in two samples taken at least twelve months apart. Once established, chronic infection can persist for decades without treatment. Its course is often silent, since people who have chronic HCV often have no symptoms and can live for many years without feeling sick.

Progression is the central concern of the chronic phase. Hepatitis C can lead to persistent infection in a high proportion of infected individuals, and can progress to chronic liver disease, cirrhosis and hepatocellular carcinoma. The underlying process is chronic inflammation of the liver, which drives the deposition of scar tissue, or fibrosis, that can eventually become cirrhosis. The pace varies with age at infection, sex, alcohol use, metabolic factors, co-infection with HIV or hepatitis B, and immune status. The risk of cirrhosis in people with chronic infection is 15–30% within 20 years. Progression can be faster in particular settings; in patients who have had liver transplants, for example, the rate of progression to fibrosis is more rapid.

Cirrhosis and hepatocellular carcinoma are the main routes to hepatitis-related death. WHO estimated that in 2024, approximately 239 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).

Clinical presentation

Hepatitis C is often clinically silent. Acute infection is usually asymptomatic, and when symptoms do appear they tend to be mild and non-specific, such as fatigue, fever, nausea, loss of appetite, abdominal discomfort, dark urine and jaundice. Acute icteric hepatitis occurs only occasionally. Because the early phase rarely announces itself, most people do not know they have been infected when the virus becomes established.

Chronic infection is typically quiet for years. Many people with chronic hepatitis C report only vague complaints, most often fatigue or malaise, and these symptoms cannot reliably be attributed to the virus itself. As a result, the large majority of chronic cases are found incidentally, when routine blood work shows raised liver enzymes such as alanine aminotransferase, or only after cirrhosis has already developed. Even in patients with cirrhosis, symptoms may remain non-specific for a long time, so the absence of complaints offers little reassurance about the state of the liver.

Specific signs of advanced liver disease emerge mainly when fibrosis has become severe and the liver can no longer perform its synthetic and filtering functions. These signs arise from portal hypertension and reduced liver function. Typical examples include ascites, which presents as abdominal distension and ankle swelling; variceal bleeding, which presents as vomiting blood or passing black stools; and hepatic encephalopathy, which presents as confusion, personality change or reversal of the sleep-wake cycle. Thrombocytopenia (a low platelet count, which may cause easy bruising), pruritus and jaundice may also be seen. These complications are the main reason patients with decompensated disease are admitted to hospital.

Extrahepatic manifestations are an important part of the clinical picture and sometimes the first reason a patient seeks care. Proposed mechanisms include direct viral injury to cells, deposition of immune complexes in small vessels and glomeruli, formation of autoantibodies, proliferation of lymphocyte clones, and inflammatory damage to tissues. The most thoroughly documented entity is mixed cryoglobulinemia, whose classic features are palpable purpura, weakness and arthralgia. Palpable purpura, which usually begins on the lower limbs, is the most common skin finding, and leukocytoclastic vasculitis is the typical histological pattern. Other reported features include Raynaud phenomenon, sensory or sensory-motor peripheral neuropathy, arthralgia that is typically symmetrical and non-erosive, sicca symptoms, membranoproliferative glomerulonephritis, lichen planus, porphyria cutanea tarda, diabetes and B-cell lymphomas. Frequency estimates vary widely between studies. In one study of 189 patients, about a quarter had liver disease that was previously undiagnosed and presented first with extrahepatic symptoms. Risk of these manifestations appears to rise with older age, female sex and advanced fibrosis.

Because so many of these features are non-specific or overlap with common rheumatological, renal and dermatological conditions, the differential diagnosis depends on testing for the virus rather than on symptoms alone. A 2009 multinational study found anti-HCV antibodies in 8.7% of patients consulting for autoimmune diseases, compared with 0.4% of healthy controls, although many of those results were not confirmed by viral RNA or genotyping. Clinicians are therefore advised to consider hepatitis C in patients with unexplained vasculitis, glomerulonephritis, cryoglobulinemia or some lymphomas, particularly when autoimmune or renal disease is present without a clear cause.

Diagnosis and staging

Screening usually starts with an antibody test that checks the blood for HCV-specific IgG. Third-generation tests have been reported to reach sensitivity and specificity above 99%. Because such a test reflects exposure at any point in the past, a reactive result cannot by itself show whether the infection is still active. The antibody test can stay positive in most patients even after they have recovered. Timing also matters. If an antibody result is negative within the first eight weeks after infection, the test should be repeated after eight weeks to check for seroconversion. RNA testing is recommended for people who might have been exposed within the past six months, whatever their antibody result.

A reactive antibody result is followed by a test for viral RNA, usually a PCR-based nucleic acid test. The CDC advises clinicians to collect every sample needed for diagnosis at one visit and to order RNA testing automatically when the antibody test is reactive. RNA usually becomes detectable one to two weeks after exposure, and a detectable result indicates current infection. Antibody-positive people whose RNA is undetectable have typically cleared the virus on their own, usually within 6–12 months of initial infection, or have been cured by treatment. Such results are read as showing no evidence of active infection, although the person is not protected from reinfection. Where PCR is unavailable, core antigen assays can serve as a cheaper alternative. They are stable at room temperature, but their detection limit is far higher, roughly 3000-10000 IU/mL of HCV RNA, compared with 12-15 IU/mL for PCR assays.

Quantitative RNA measurement, which reports viral load, serves several purposes. Clinicians use it to measure a patient's baseline viral load prior to starting HCV therapy, to follow the response during treatment, and to determine whether a sustained virologic response has been reached. Some quantitative assays detect very low concentrations; one FDA-approved assay has a limit of detection of 3.9 IU/mL in plasma. Genotyping is performed alongside quantification to identify which viral genetic group is present, and its role in selecting regimens is discussed in the treatment section.

Staging of liver fibrosis has changed considerably. Liver biopsy was historically considered the gold standard for pretreatment evaluation of fibrosis in chronic hepatitis C. Biopsy is invasive and carries a risk of complications, which motivated the search for alternatives. Transient elastography is one such alternative: it uses ultrasound shear waves to estimate liver stiffness, which serves as a measure of fibrosis, and to derive a controlled attenuation parameter for steatosis. In chronic hepatitis C, TE has been validated with a sensitivity of 89% and a specificity of 91% for detecting advanced fibrosis. Serum-based indices, such as the FIB-4 score and the aspartate aminotransferase-to-platelet ratio index, provide further noninvasive options. In one study of HIV–HCV coinfected patients, elastography had significantly higher diagnostic accuracy for F≥3 than four other noninvasive indices. Its replacement of biopsy has not been uniform, however: an earlier review judged that its clinical usefulness was not firmly established and that it could not yet replace biopsy for detecting significant fibrosis. Fibrosis is typically graded on the METAVIR scale, in which liver biopsy specimens are staged F0–F4.

Treatment response is judged by sustained virologic response (SVR). It is defined as the continued absence of detectable HCV RNA for at least 12 weeks after completion of therapy, and the testing is performed with a sensitive assay that typically has a lower limit near 25 IU/mL. Quantitative HCV RNA testing is recommended 12 or more weeks after completion of therapy to document SVR, which is consistent with cure. Among people who achieve SVR12 with direct-acting antiviral therapy, more than 99% remain free of detectable virus durably. A four-week measurement (SVR4) has high concordance, on the order of 98–99%, with SVR12 and could be considered as an alternative endpoint, but SVR12 remains the consensus outcome. Cured people can still be reinfected, so persons cured of HCV can become reinfected with HCV, and testing is needed after any new exposure.

Treatment before and after direct-acting antivirals

Interferon-based therapy

For most of the first two decades after the virus was identified, treatment rested on interferon. Interferon monotherapy yielded sustained virological response (SVR) rates of only 10 to 20 percent, and it carried heavy toxicity, including flu-like symptoms, cytopenias and neuropsychiatric complications. Adding ribavirin, a guanosine analogue, to interferon from the 1990s onward significantly increased treatment efficacy by decreasing the risk of post-treatment viral relapse. The later switch to pegylated interferon, which lasts longer in the body, gave higher response rates, especially in non-genotype 1 infections, though the combination also brought additional side effects such as anemia and depression. Across the large trials of the early 2000s, which enrolled mixed genotypes, the combination produced sustained response in roughly half of participants, which is the origin of the "around half" figure often quoted for the common genotype 1.

First-generation DAAs

The first direct-acting antivirals (DAAs) were protease inhibitors. The arrival of telaprevir and boceprevir marked a significant milestone, because combined with peginterferon and ribavirin, these protease inhibitors boosted response rates in patients with genotype 1 infection. These drugs still required the interferon backbone, which kept treatment long and unpleasant. High rates of adverse effects and drug resistance remained challenges. In one 2013 review, serious adverse events affected 16% of patients on 24 weeks of telaprevir-based triple therapy, compared with 4.7% on peginterferon with ribavirin.

Interferon-free regimens

Later DAAs targeted the NS5A protein and the NS5B RNA polymerase, which made it possible to drop interferon altogether. Sofosbuvir, an NS5B polymerase inhibitor, and ledipasvir, an NS5A inhibitor, were combined in one of the first such regimens. In the 2014 trials of this combination, the 12-week course achieved an SVR of 97% in untreated patients with genotype 1 infection, and a 24-week course gave 99%. Second-generation DAAs, such as sofosbuvir and ledipasvir, introduced interferon-free regimens with improved safety profiles and efficacy. Most such regimens shortened treatment to roughly eight to twelve weeks, and early interferon-free trials showed that treatment could be given without the injections and systemic side effects that had limited earlier therapy.

Pangenotypic regimens and current practice

The most recent generation of fixed-dose combinations works across all genotypes. Widely used examples include sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, both of which provide pangenotypic coverage. Sofosbuvir/velpatasvir has been approved for chronic HCV genotypes 1 through 6 without ribavirin, in patients with or without compensated cirrhosis, with weight-based ribavirin reserved for decompensated cirrhosis. Pangenotypic regimens are not uniformly applied to every subgroup, however. For example, glecaprevir-pibrentasvir is given for 16 weeks to people with genotype 3 infection who have previously received interferon or ribavirin, and sofosbuvir-based regimens for genotype 3 have required longer courses. Because a single regimen can be used across genotypes, the need for genotype testing before starting therapy has largely fallen away in routine practice, although genotype remains relevant for some decisions in complex cases.

Current treatment, monitoring and special populations

Treatment is generally offered to all people with chronic infection, whatever the stage of their liver disease, with priority for those with advanced fibrosis. The main exception is a very short life expectancy that treatment cannot change, or cases in which liver transplantation or another directed therapy takes precedence. The goal is a sustained virologic response (SVR), defined as undetectable HCV RNA at least 12 weeks after treatment ends, which is treated as equivalent to a cure. Direct-acting antiviral (DAA) regimens have reported SVR rates of 90% or higher across treatment-naive and treatment-experienced patients, with and without cirrhosis.

Patients with decompensated cirrhosis need closer management. In a pilot cohort of 100 treatment-naive patients, 50 with compensated and 50 with decompensated cirrhosis, the decompensated group received a longer course (24 weeks, compared with 12 weeks for compensated disease). Virological response was nearly universal, but the decompensated group had a 10% mortality rate, with deaths during treatment from variceal bleeding and other causes. The authors concluded that liver function and disease severity, rather than viral load, drove these outcomes. Regimen choice and dosing also need to be adjusted for impaired kidney function, and people with HIV coinfection require attention to antiretroviral interactions. Patients who have been treated before may need a different regimen or a longer course, depending on the earlier response.

Pregnancy presents the most difficult decisions. Current guidance recommends HCV testing for everyone planning a pregnancy and repeated screening in each pregnancy. It also advises pregnant patients with chronic infection to defer DAA treatment until they are no longer pregnant or breastfeeding. Small studies, however, have reported favourable results when DAAs were given during pregnancy. A prospective trial of eight people who completed a 12-week course at about 23 weeks of gestation found no clinically meaningful differences in drug exposure and no mother-to-child transmission. An interim report from an ongoing multicentre study of sofosbuvir/velpatasvir in 35 pregnant participants described 100% SVR at 12 weeks, with no transmission to the fetus. Infants born to infected mothers are usually tested, and those with undetectable RNA at or after two months of age need no further follow-up. DAAs are recommended for children aged three years and older.

Ongoing management after treatment includes confirming SVR, usually by RNA testing about 12 weeks after the end of therapy. Surveillance for liver cancer continues for patients who had significant fibrosis or cirrhosis, because risk can persist after the virus is cleared. Drug interactions with antiretrovirals, anticonvulsants and acid-suppressing medicines must be checked before treatment begins, and adherence matters because missed doses can allow resistance to develop. Patients who continue to inject drugs face a risk of reinfection, so retesting after cure is an important part of follow-up.

Prevention and harm reduction

No vaccine against hepatitis C is currently licensed, so prevention relies on measures that cut off the routes by which blood reaches another person. The World Health Organization's core list includes safe use of health-care injections, safe handling and disposal of needles and medical waste, testing of donated blood, condom use, and harm-reduction services for people who inject drugs. Modelling studies of HCV among people who inject drugs generally found that harm reduction alone is unlikely to reach elimination targets.

Because the vast majority of new HCV infections occur among people who inject drugs, harm-reduction programmes are central to prevention in high-income settings. Needle and syringe programmes provide sterile equipment and disposal of used injecting equipment, and are associated with an estimated 50% reduction in HIV and HCV incidence. Opioid agonist therapy (OAT) with methadone or buprenorphine also lowers exposure: it reduces an individual's risk of HCV acquisition by 50% among PWID. According to a review of the treatment literature, combined OST and high-coverage needle and syringe programs can reduce HCV incidence by up to 80%. Supervised consumption services are also used in some settings to reduce the same risks, although their effect on HCV specifically is less clearly quantified.

Treatment as prevention (TasP) is a newer strategy that draws on the HIV model but differs in one key respect. In contrast to HIV, HCV is curable and therapy is finite. In the HCV version of the approach, future transmission is reduced by treating affected individuals, and people who are cured have fewer opportunities to transmit the virus. Modelling suggests that this effect is substantial. TasP can greatly reduce HCV prevalence, incidence of infection, and incidence of reinfection in PWID, but its impact depends on how many people are treated and on whether treated people change their injecting behaviour. Its effect is also shaped by the structure of injecting partnerships, because the prevalence among a person's partners affects their exposure after treatment.

Reinfection after cure is the main limit on this approach. Studies show that the rate of hepatitis C reinfection is lower than the rates of primary infection reported in the literature for this population, and this has led to the conclusion that reinfection should not be used as a reason to withhold therapy from people who are still injecting. Rates vary widely between settings. In a needle and syringe programme in Stockholm, the reinfection rate after sustained virologic response was 9.3 per 100 person-years, and reinfection was associated with younger age, treatment received while in prison, and homelessness. The rate of reinfection was lowest among people receiving opioid agonist therapy with no recent drug use.

For these reasons, the evidence points towards integrated services rather than single interventions. Harm reduction services are required to reduce the reinfection risk, while regular post-treatment hepatitis C assessment is required for early detection and retreatment. Programmes that combine testing, DAA treatment, OAT and addiction care, and that retest people who remain at risk, are therefore regarded as the most practical way to sustain the gains from curative treatment.

Global burden and epidemiology

The World Health Organization's most recent global estimates place the number of people living with viraemic hepatitis C at about 47 million in 2024, equal to roughly 0.6 per cent of the world population. An estimated 0.9 million people were newly infected with HCV that year, a decline of only 8 per cent since 2015, well short of the 2030 target of an 80 per cent reduction. These figures are prevalence and incidence estimates modelled from survey and surveillance data, and they have been revised over time. The 2024 WHO report had put the 2022 figure at nearly 1.0 million new hepatitis C infections, and the revisions are based on improved data from prevalence surveys. The 95% uncertainty range around the current prevalence estimate is wide, at 31 million to 71 million people.

Infection occurs in every WHO region, but the burden is uneven. The highest burden of disease is in the Eastern Mediterranean Region with 12 million people chronically infected. The South-East Asia Region and the European Region each have about 9 million chronically infected people, and the Western Pacific Region has 7 million. The African Region and the Region of the Americas have about 8 million and 5 million respectively. Crude counts and proportions do not coincide. Seroprevalence is highest in parts of North Africa and the Middle East, where Egypt has stood out for decades; one meta-analysis estimated that an estimated 14.7% of the total population was seropositive for HCV, although that figure predates current surveys. By contrast, the largest absolute numbers are concentrated in a small group of populous countries. In 2024, 10 countries accounted for 58 per cent of global cases: China, India, Indonesia, Japan, Nigeria, Pakistan, Russia, South Africa, the United States and Viet Nam.

Genotype distribution follows regional patterns that reflect historical transmission routes. A large review of genotyped samples found that infections in the Caribbean, Latin America, North America and Europe are predominantly caused by genotype 1, while North Africa and the Middle East have a large genotype 4 population, probably attributable to the high prevalence of genotype 4 in Egypt, where genotype 4 accounts for 93.1% of genotyped cases. In Asia, genotype 3 is largely driven by its high prevalence in South Asia, and within the region HCV genotype 3a continues to be the most prevalent subtype infecting people in Pakistan. Because these proportions come from studies that genotyped only subsets of patients, they describe typical patterns rather than exact national totals.

Deaths from hepatitis C are less concentrated than infections. WHO estimates that approximately 239 000 people died from hepatitis C in 2024, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). The death toll has fallen only modestly, with hepatitis C deaths a 12% reduction since 2015. Over the same period, hepatitis B caused a larger and growing burden: chronic HBV infection caused about 1.1 million deaths, an increase of 17% since 2015. Because cirrhosis and liver cancer develop over decades, current mortality reflects infections acquired many years earlier, so falling incidence will reduce deaths only gradually.

The statistics also show a large gap between infection and care. WHO reports that 36% (95% UI: 17-57%) knew their diagnosis among the cumulative total ever infected during 2015–2024, and that around 20% (95% UI: 10–31%) had been treated with DAAs by the end of 2024 among those diagnosed. Undiagnosed infection is therefore the main reason the prevalence figure remains high, and the regional differences in diagnosis rates are themselves an epidemiological finding, since awareness is highest in the Eastern Mediterranean region and lowest in the African and South-East Asian regions.

Policy, elimination targets and access

The World Health Assembly endorsed a global viral hepatitis strategy in 2016, and its 2030 aims are measured against 2015 baselines. The overall goal is a 90% reduction in new hepatitis infections and a 65% reduction in hepatitis-related deaths. For hepatitis C specifically, the World Health Organization set quantitative benchmarks of no more than five new infections and no more than two deaths per 100,000 people per year. The WHO's Path to Elimination framework groups countries into bronze, silver and gold tiers according to how many infected people are diagnosed and treated and how far harm-reduction services, such as needle and syringe provision and opioid agonist therapy, are in place.

Progress has been real but uneven. The WHO's 2026 global hepatitis report recorded a 12% fall in hepatitis C-related deaths since 2015, but it concluded that current rates of change are insufficient to meet all the 2030 targets. A 2025 analysis of national data found that only 25 countries (15%) had reached the mortality benchmark and 24 (14%) the incidence benchmark, and that only 10 countries (6%) met both. Treatment numbers illustrate the gap. Across hepatitis B and C combined, the number of people receiving treatment rose from about 1 million to 9.4 million over roughly five years, far below the 2030 target of 40 million. The WHO attributes the remaining shortfall largely to stigma, weak health systems and inequitable access to care.

Access is shaped above all by price. Direct-acting antivirals (DAAs) have been sold at very different prices across income groups, from under US$100 to around US$40,000 per course. Launch prices in the United States were about US$66,000 and US$84,000 for a 12-week course of simeprevir and sofosbuvir respectively, and in many systems negotiated prices are held as confidential contracts, which limits transparency for public payers. Estimates of production cost are far lower: one modelling study concluded that two- or three-drug combinations could be manufactured at minimum prices of US$100–250 per 12-week course, and generic versions have been sold for under US$500 in some countries. Other obstacles include limited testing capacity, restrictions on which patients qualify for treatment, and stigma toward people who use drugs. Price competition also has an effect in higher-income markets: in 2017, authorized generics introduced in the United States were priced at US$36,000 and US$24,000 per course, well below the original list prices.

Expanded access has relied on several mechanisms. Governments and agencies have used voluntary and compulsory licences, patent opposition, joint procurement and personal importation schemes to obtain cheaper drugs, and tiered pricing agreements have set different prices by national income level. Such measures have expanded treatment in some countries, but they depend on negotiation and on the legal space available to each government, so their reach remains uneven.

Several jurisdictions have adopted micro-elimination, which pursues elimination goals within a defined population or setting. Taiwan began a free DAA programme in 2017 aimed partly at people living with HIV, and a 2022 agent-based model of people who inject drugs in metropolitan Chicago estimated that reaching the WHO goal there would require about US$325 million in DAA costs, with most enrolled individuals needing a single course but some needing several because of reinfection. The same model projected a 28% increase in costs under low adherence. In Europe, a civil-society monitoring study of 25 countries found that treatment in prisons had increased between 2020 and 2021, but it judged overall progress toward the WHO goals to be insufficient.

Immunity and the challenge of a vaccine

The innate immune system is the first line of defence. Infected liver cells and immune cells sense viral RNA through pattern-recognition receptors, which triggers an interferon response and the expression of antiviral genes. HCV has evolved ways to disrupt this signalling, and this interference gives the virus time to establish infection before adaptive immunity matures.

Adaptive immunity, mediated by T cells and antibodies, is the main determinant of whether an infection resolves. Only a minority of acutely infected people clear the virus spontaneously, with estimates of roughly 10 to 15 percent. Those who do so typically mount strong, broad and early virus-specific T-cell responses, and in at least some individuals neutralising antibodies emerge around the time viraemia falls. One long-term case study found that clearance coincided with the appearance of neutralising antibodies and with a reversal of T-cell exhaustion. Antibodies are not strictly required, however: people with congenital agammaglobulinaemia have been reported to resolve acute infection, although antibodies made during infection do not appear to prevent reinfection.

Chronic infection is marked by progressive T-cell dysfunction. Virus-specific CD8 T cells lose effector function and express inhibitory receptors such as PD-1, while CD4 help weakens, with reduced interleukin-2 production limiting proliferation and interferon-gamma output. Regulatory T cells and the immunosuppressive environment of the liver contribute further. The virus also mutates within the epitopes that T cells recognise, so the immune system is repeatedly pursuing a moving target. Even after direct-acting antivirals cure the infection, treated people show a memory-like T-cell profile that differs from that of people who cleared the virus spontaneously, a pattern sometimes described as an immunological scar. Among people who inject drugs, partial exhaustion has been observed after treatment, and this is one reason reinfection can follow cure.

Vaccine development has pursued two main strategies. Envelope-based vaccines using E1 and E2 glycoproteins can elicit antibodies that neutralise a range of genotypes, but in humans the neutralising responses are concentrated on a limited region of E2 and their breadth is generally insufficient, so protection against infection has not been achieved. Viral-vector vaccines encoding non-structural proteins aim to induce T-cell responses instead. The most advanced of these, a viral-vectored NS3–NS5 candidate evaluated in a phase 2 efficacy trial among people who inject drugs, induced HCV-specific T-cell responses in most vaccinees and had limited viraemia in preclinical chimpanzee studies. However, it did not prevent chronic infection in the trial population, which showed that a T-cell response alone was insufficient. Peptide-based and other T-cell vaccines have shown low reactogenicity and some immunogenicity, but their effects on viral load have been small or transient, and their clinical benefit has not been demonstrated.

Several factors make the vaccine problem especially difficult. The virus's extreme genetic diversity means that a vaccine must cover many variants, and the lack of a small-animal model complicates early testing: chimpanzees are no longer available for research, and primary human hepatocytes do not survive long enough in culture to support chronic infection, so most laboratory work relies on hepatoma cell lines. Proposals to accelerate development include controlled human infection models, in which volunteers are infected with HCV and then cured with antivirals. These models raise serious ethical questions about informed consent and risk, and modelling studies suggest that imbalances in infection rates between trial arms can distort efficacy estimates. Protein-based candidates are now entering early-phase testing, and no HCV vaccine has yet been licensed.

Liver disease and related complications

Chronic hepatitis C damages the liver through a repeating cycle of hepatocyte injury, immune-mediated inflammation and repair. Over years, the repair process deposits collagen and other extracellular matrix material, producing fibrosis. The pace of this process varies widely between people. Progression from early fibrosis to cirrhosis typically takes one to several decades, and host and viral factors shape the timeline. Age at infection, alcohol intake, sex, metabolic health, coinfection with HIV or hepatitis B, and immune status all influence how quickly scarring advances. Once cirrhosis is established, the liver's architecture is permanently distorted and its capacity to process blood, make proteins and clear toxins becomes impaired.

Cirrhosis carries the highest risk of hepatocellular carcinoma (HCC), the most common primary liver cancer. Eradicating the virus lowers this risk substantially but does not remove it. A cohort study from Sweden found that the risk persisted long term after sustained virologic response (SVR) in patients with cirrhosis, and a later cohort reported elevated risk for up to ten years after eradication in patients with baseline cirrhosis or high FIB-4 scores. Some patients also develop HCC despite having only mild or no fibrosis, which is one reason surveillance recommendations differ between professional societies. Case reports have described tumours diagnosed more than two decades after successful interferon therapy, underscoring that the risk does not reach zero by any fixed time point. By contrast, people who clear the virus spontaneously during acute infection, without ever developing chronic liver injury, appear to have a very low or negligible HCC risk. Persistent changes in host gene expression after infection have been proposed as a possible contributor, but cirrhosis appears to be the critical determinant.

Portal hypertension is the main mechanism behind the serious complications of advanced liver disease. Scarring increases resistance to blood flow through the liver, while blood flow from the splanchnic circulation into the portal system rises, so pressure in the portal vein increases. Portal-systemic collateral vessels then form, giving rise to varices and ascites. The hepatic venous pressure gradient (HVPG) is the reference measure; values above about 10 mmHg are associated with a higher risk of complications, and variceal bleeding typically occurs when the gradient exceeds about 12 mmHg. The three principal clinical consequences are ascites, which is the most common complication of cirrhosis, variceal haemorrhage, and hepatic encephalopathy, a neuropsychiatric syndrome caused by the accumulation of toxins that the liver no longer clears. Related complications include spontaneous bacterial peritonitis, hepatorenal syndrome, and thrombocytopenia, which results partly from splenic sequestration of platelets. Together these conditions account for much of the hospitalisation and mortality seen in people with decompensated disease.

Metabolic factors add a further layer of risk. Insulin resistance and hepatic steatosis are common in chronic infection and can coexist with obesity and type 2 diabetes. Cardiometabolic conditions, including type 2 diabetes, have been identified as risk factors for HCC that develops after SVR, and metabolic dysfunction-associated steatotic liver disease has been linked to a higher likelihood of post-SVR HCC in some cohorts. This suggests that liver health after cure depends partly on factors unrelated to the virus. The effect of treatment on portal hypertension is also an active area of study. Interferon-based therapy and, more recently, direct-acting antivirals have both been associated with reductions in portal pressure, although the evidence for direct-acting antivirals is still limited. Patients who already have clinically significant portal hypertension remain at risk of decompensation for several years after successful treatment, so they require continued monitoring for both varices and HCC.

Development of treatment and research history

For roughly two decades after the first clinical trials, interferon-based therapy was the only realistic option. A 1986 pilot study reported a benefit from alpha interferon in what was then called non-A, non-B hepatitis, and that result encouraged many randomized trials of the drug. In 1990 Ribavirin was first proposed to treat HCV infection and the first clinical trial for the assessment of its efficacy began in 1991. The pegylated form of interferon reached the market in 2001, and the combination with ribavirin then became the standard of care. Even so, results were modest: an earlier study found that interferon with ribavirin produced a sustained response in only about 40% of patients with genotype 1 infection.

From the mid-1990s, research shifted toward the virus's own enzymes and proteins. Screening programmes began to look for inhibitors of the NS3 serine protease in 1995 and of the NS5B RNA-dependent RNA polymerase in 1996, and an interferon-free trial started in 2008. NS5B is an essential enzyme that makes new viral RNA, which is why it became an attractive drug target. Work on cell-culture systems and subgenomic replicons in the late 1990s and early 2000s gave researchers a way to test compounds against viral cells in the laboratory. Replication occurs within a membrane-bound replicase complex in the endoplasmic reticulum, and NS5A is necessary for building this structure. Later work showed that NS5A can by itself induce the membrane changes, which helped to establish it as a target. Proof of concept for an NS5A inhibitor, daclatasvir, was reported in 2008. Small molecules targeting a viral protein without any known enzymatic activity can also have profound antiviral effects.

The first direct-acting antivirals (DAAs) were protease inhibitors. Telaprevir and boceprevir were each approved as direct-acting antiviral agents. They were given together with pegylated interferon and ribavirin, and their approval in 2011 followed nearly a decade of minimal progress in the development of treatments for HCV infection. Their benefits came with a heavy burden of adverse effects and a risk of resistance, so the combinations still depended on interferon. Sofosbuvir, a nucleotide analogue that inhibits NS5B and was identified in 2010, was developed to reduce or eliminate the need for peginterferon.

The shift to all-oral therapy came quickly after that. In December 2013 the US Food and Drug Administration approved sofosbuvir, described as the first all-oral, interferon-free regimen for the disease. Subsequently, sofosbuvir became the first DAA to have an FDA-approved indication for treatment of HCC patients awaiting liver transplantation. Simeprevir, a second-generation NS3/4A protease inhibitor, was approved in November 2013. Sofosbuvir was also the first oral interferon-free regimen for patients co-infected with HIV, and the combination of ledipasvir and sofosbuvir, given as a once-daily single tablet, followed for genotype 1 infection in 2014. These approvals made it possible to treat patient groups who had few options, including those who had failed earlier therapy, had cirrhosis, or could not tolerate interferon.

The speed of this change is why DAA development is widely cited as an example of how rational antiviral discovery can alter the course of a chronic infection. The field moved from interferon's general immune-modulating effects to drugs designed against specific viral targets within about two decades, and this sequence is now often discussed alongside the broader question of how quickly new treatments reach the populations who need them most.

Comparison with other hepatitis viruses

The five hepatitis viruses (A to E) share a target organ but differ in how they spread, whether they become chronic, and whether they can be prevented. Hepatitis A virus (HAV) is spread mainly by the faecal–oral route, through contaminated water, food or close personal contact, so its control depends heavily on sanitation and hygiene. HAV does not establish chronic infection: most people recover fully and keep lasting immunity, and a vaccine is available. Death is rare and occurs mostly through fulminant liver failure, which is more likely in older people and those with existing liver disease.

Hepatitis B virus (HBV) shares several transmission routes with hepatitis C, including sexual contact, injection drug use and unsafe injections, and it adds perinatal transmission as a major pathway. Age at infection largely determines its course: chronic disease follows in less than 5% of adult infections but in about 95% of infections acquired in infancy or early childhood. Unlike HCV, HBV can be prevented by a safe and effective vaccine, which is why infant vaccination is the central strategy against it. The two viruses therefore call for different responses. Vaccination protects against HBV, whereas HCV has no vaccine and must be managed through testing, antiviral treatment and prevention of exposure. Because the two viruses can infect the same person, HCV infection may also suppress HBV to undetectable levels, which complicates testing, and HBV status is checked before antiviral treatment for HCV.

Hepatitis D virus (HDV) is a small, defective RNA virus with a genome of roughly 1,700 nucleotides. It cannot complete its life cycle alone. It borrows the HBV surface antigen to form its envelope, so it can infect only people who have hepatitis B, either through simultaneous coinfection or through superinfection of a person with chronic HBV. Its envelope is built from HBV proteins, and HDV therefore depends on HBV for entry and secretion. Coinfection and superinfection produce more severe disease than HBV alone. Acute HDV carries a high risk of death, and chronic HDV carries a higher risk of cirrhosis and liver cancer than HBV monoinfection, which is why it is generally regarded as the most severe form of viral hepatitis. Because HDV cannot occur without HBV, HBV vaccination also prevents HDV, a dependence that has no counterpart in HCV.

The contrast explains the absence of a hepatitis C vaccine. The HBV vaccine relies on a surface antigen that is comparatively stable, and infection with HBV or HAV usually induces durable protection. HCV, by contrast, is highly variable, its envelope glycoproteins E1 and E2 change rapidly within each host, and infection often persists long enough to exhaust the immune response. These features make it difficult to design a vaccine that induces broad, lasting protection. Reinfection after cure is also possible, which means a person who has cleared HCV is not protected against a new infection.

These differences shape public health strategy. Hepatitis A and B programmes rest largely on vaccination, with HAV also addressed through sanitation and outbreak response, while HBV programmes add birth-dose vaccination and antiviral treatment to prevent mother-to-child transmission. Hepatitis C programmes focus on antibody screening, RNA confirmation, direct-acting antiviral treatment and harm reduction. Overlapping risk groups, such as people who inject drugs, people with HIV and people with chronic liver disease, mean that services are often combined. Hepatitis A vaccination is recommended for people with chronic liver disease, and integrated testing for HBV and HCV is common in clinics that serve people who use drugs. Such integration reflects the fact that the viruses share routes of exposure but differ in the tools available to control each one.

Ethics, stigma and social determinants

Hepatitis C falls most heavily on people who are already socially marginalised. Poverty, incarceration and injection drug use often overlap, and each shapes whether a person is tested, linked to care and kept in treatment. Prisons are one example: in Canada, antibody prevalence among prisoners has been reported at up to 40 times the national average. Because the virus is most often acquired through shared, unsterile injecting equipment, the disease has also become attached to moral judgements that extend well beyond the medical facts, which is part of why the social determinants of health matter so much to elimination.

Stigma operates at several levels. Many people who inject drugs describe internalised shame that leads them to conceal their drug use or their hepatitis C status from clinicians. Interpersonal stigma appears as judgement from physicians, and some patients report that treatment was withheld because they were still using substances. Others were told they had to abstain from drugs or alcohol before they could be treated, and came to feel they had to prove they were "worthy" of a cure. Some interviewees also reported hearing that treating people who inject drugs was a waste of time, or that retreatment would be refused after reinfection. For many, the burden of these experiences outweighs the perceived benefits of seeking care. Stigma also discourages use of harm-reduction programmes such as needle and syringe services, which reduce the transmission that the stigma is attached to.

Barriers are not only attitudinal. In rural areas, distance from clinics, limited transport, weak phone and internet connectivity, unstable housing and concern about medication costs compound one another, and people who inject drugs in these areas are reportedly tested less often than their urban counterparts. Services designed specifically for people who use drugs can lower these obstacles, although some patients find that attending them requires disclosure and feels stigmatising. Qualitative studies have found that peer support and wraparound services, which address housing, food and mental health alongside treatment, help people stay engaged in care.

Equity questions also arise in drug pricing, which is a matter of economics as much as clinical practice. A 2015 analysis of originator direct-acting antiviral prices found that a bottle of sofosbuvir ranged from US$300 in India and Pakistan to US$20,590 in Switzerland, and that some middle-income countries paid more than wealthier ones. Côte d'Ivoire paid almost three times India's price for sofosbuvir despite a much lower national income. Generic competition has since narrowed these gaps: WHO-prequalified generics of sofosbuvir and daclatasvir have been available for as little as US$60 per 12-week course, and modelling had earlier suggested that minimum target prices of US$100 to US$250 were achievable. High prices nonetheless remained a barrier seven years after the drugs were introduced, according to a 2020 study of 50 countries. Governments have pursued voluntary and compulsory licences, patent opposition, joint procurement and price negotiation as ways to widen access.

Integrated health-system models that bring testing, treatment and addiction support into one setting have produced measurable results. In England, the HITT initiative screened more than 95% of residents across 13 prisons and started direct-acting antiviral treatment in over 75% of those with active infection between January 2020 and September 2021. A retrospective study of 32 male prisoners found that their sustained virologic response rates did not differ significantly from those of outpatients, although loss to follow-up was a major reason for discontinuation. Studies of custodial care suggest that discharge planning and patient navigation after release are needed to keep people in treatment, and a Spanish programme for people serving community sentences reached a 92.8% screening rate using point-of-care tests and a navigator. The evidence so far comes mainly from small, local programmes, so its applicability to public-health systems at national scale depends on how these models are funded and sustained.

Open questions and future directions

A prophylactic vaccine remains the most significant unmet goal. Because HCV mutates rapidly and escapes neutralising antibodies, the main design problem is finding an antigen that can provoke antibodies active against many strains at once. Recent preclinical work has tried several approaches. A soluble, native-like form of the E1E2 envelope heterodimer induced neutralising activity against all tested genotypes in immunised mice, with greater breadth than the membrane-bound complex. Separately, epitope-focused immunogens that display two cross-neutralising epitopes produced antibodies that neutralised four diverse strains in mice carrying human antibody genes. Human data also point in a useful direction. Memory B cells in a person who cleared the virus about 25 years earlier were still able to produce broadly neutralising antibodies, which suggests that some protective responses are durable. Yet the same work indicated that more than one site on E2 may need to be targeted. Only two prophylactic candidates have reached clinical trials, with limited success, and the lack of small-animal models has slowed preclinical testing.

A second open question concerns the large population that does not know it is infected. Diagnosis depends on laboratory confirmation, and many people with chronic infection have no symptoms until the liver is already damaged. Closing this gap requires point-of-care RNA tests that can be used in primary care, prisons, harm-reduction services and other places where people at risk already come into contact with health services. Testing strategies also need to be built into those settings rather than relying on referral to specialist clinics, because people who inject drugs and other high-risk groups are often least likely to reach conventional care. Achieving elimination depends on whether such approaches can find infections quickly enough to make a difference to transmission.

The long-term incidence trajectory in the direct-acting antiviral era is still under evaluation, and reinfection is central to that question. Pooled estimates for people who inject drugs after successful treatment have been around 6 cases per 100 person-years in meta-analyses, but individual cohorts vary widely. In one study of people with recent injecting drug use in Australia, reinfection reached about 9.7 per 100 person-years overall and was higher among those who shared needles or syringes. In a Scottish cohort, reinfection among people treated with direct-acting antivirals was numerically higher than among those treated with interferon-based regimens, although the difference was not large. Other cohorts, including a study published in Annals of Internal Medicine, reported much lower rates of about 1.7 per 100 person-years. Data from low- and middle-income countries are sparse, and a systematic review found an extremely wide range of estimates. Whether reinfection can be controlled will depend on the availability of opioid agonist therapy, needle and syringe services and integrated care, and on whether policies restrict access for people who use drugs.

Questions also remain about liver cancer risk after cure. Modelling studies estimate that people with cirrhosis who achieve a sustained virologic response still face a residual risk of roughly 2.2 percent a year, so surveillance is still recommended for this group. For people with advanced fibrosis but not cirrhosis, guidelines from different liver societies vary, and no clear consensus has emerged on whether six-monthly ultrasound is needed. Risk-stratification algorithms that combine post-treatment age, albumin, liver stiffness and other markers have identified a large share of patients, around two-thirds in one derivation and validation study, whose annual risk falls below commonly used cost-effectiveness thresholds. Metabolic factors appear to matter as well: a cohort from Taiwan reported that severe steatosis and diabetes or prediabetes each roughly doubled the risk of liver cancer after viral clearance. Modelling work further suggests that improving adherence to existing surveillance may save more lives than improving the sensitivity of imaging, which is important because adherence to surveillance is currently suboptimal. How long the excess risk persists, and which patients should be monitored and for how long, remain active areas of research.

References

1. The Nobel Prize in Physiology or Medicine 2020 - Advanced information - NobelPrize.orgnobelprize.org
2. Hepatitis C virus isolate polypeptidesimage-ppubs.uspto.gov
3. Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitisacademic.oup.com
4. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control - Journal of Hepatologyjournal-of-hepatology.eu
5. Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen proteinimage-ppubs.uspto.gov
6. Hepatitis Virus Non A Non B - an overviewsciencedirect.com
7. Harvey J. Alter, Michael Houghton and Charles M. Rice receive the 2020 Nobel Prize in Physiology or Medicine for the discovery of hepatitis C virus - The Cancer Lettercancerletter.com
8. Hepatitis C scientists in the limelight: Nobel Prize 2020 - EASL-The Home of Hepatology.easl.eu
9. Hepatitis C: looking at a virus that hasn't been seen - PMCpmc.ncbi.nlm.nih.gov
10. The Nobel Prize in Physiology or Medicine 2020 - Press release - NobelPrize.orgnobelprize.org
11. Breakthroughs in hepatitis C research: from discovery to curenature.com
12. Nobel Prize in Physiology or Medicine 2020: Discovery of Hepatitis C virussciencedaily.com
13. Molecular Clones of Hepatitis C Virus: Applications to Animal Modelsacademic.oup.com
14. Solid compositionsimage-ppubs.uspto.gov
15. Genus: Hepacivirus - Flaviviridaeictv.global
16. Hepacivirus - an overviewsciencedirect.com
17. Structure, genomic organization, replication and variability of hepatitis C virus - PubMedpubmed.ncbi.nlm.nih.gov
18. An overview on hepatitis C virus genotypes and its control - ScienceDirectsciencedirect.com
19. Viral polymerase inhibitorsimage-ppubs.uspto.gov
20. Hepatitis C Virus - an overviewsciencedirect.com
21. Structure - HCV Biology - Hepatitis C Onlinehepatitisc.uw.edu
22. THE MOLECULAR BIOLOGY OF HEPATITIS C VIRUS: Genotypes and Quasispecies - ScienceDirectsciencedirect.com
23. Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy surveyncbi.nlm.nih.gov
24. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with menncbi.nlm.nih.gov
25. Dynamic modelling of hepatitis C transmission among people who inject drugs: A tool to support WHO elimination targetsbiorxiv.org
26. Urgent action to fight hepatitis C in people who inject drugs in Europencbi.nlm.nih.gov
27. Hepatitis C Transmission - National Harm Reduction Coalitionharmreduction.org
28. Pathogenesis of Hepatitis C During Pregnancy and Childhoodncbi.nlm.nih.gov
29. Predictors and incidence of sexually transmitted Hepatitis C virus infection in HIV positive men who have sex with men - PMCpmc.ncbi.nlm.nih.gov
30. Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencingncbi.nlm.nih.gov
31. Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984–2011 - PMCpmc.ncbi.nlm.nih.gov
32. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men - PubMedpubmed.ncbi.nlm.nih.gov
33. Reducing Risk for Mother-to-Infant Transmission of Hepatitis C Virus: A Systematic Review for the U.S. Preventive Services Task Forcedoi.org
34. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission - The Lancetthelancet.com
35. Mother-to-Infant Hepatitis C Virus Transmission and Breastfeedinglink.springer.com
36. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network - PubMedpubmed.ncbi.nlm.nih.gov
37. Fact sheet © WHO 2015 Hepatitis C in the WHO European Regionaph.org.ua
38. Natural history of hepatitis C Rachel H. Westbrook, Geoffrey Dusheiko⇑journal-of-hepatology.eu
39. Hepatitis C in the WHO European Region FA C T S H E E Twho.int
40. Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapyjournals.plos.org
41. Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapyncbi.nlm.nih.gov
42. Natural History of Acute Symptomatic Hepatitis Type Clink.springer.com
43. Hepatitis C Fact Sheets - Viral Hepatitis and Liver Diseasehepatitis.va.gov
44. Hepatitis Cwho.int
45. Epidemiological and Clinical Factors Associated with Spontaneous Clearance of Hepatitis C Virus - PMCpmc.ncbi.nlm.nih.gov
46. Factsheet for health professionals about hepatitis C - ECDCecdc.europa.eu
47. Hepatitis C Clinical Presentation: History, Physical Examinationemedicine.medscape.com
48. CLINICAL MANIFESTATIONS OF HEPATITIS C - ScienceDirectsciencedirect.com
49. Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitisclinicaltrials.gov
50. Extrahepatic symptoms as presenting manifestations of hepatitis C virus infection - PubMedpubmed.ncbi.nlm.nih.gov
51. Extrahepatic manifestations of hepatitis C - PMCpmc.ncbi.nlm.nih.gov
52. Clinical manifestations and natural history of chronic hepatitis C virus infection - UpToDateuptodate.com
53. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapyncbi.nlm.nih.gov
54. Morphologic Features of Extrahepatic Manifestations of Hepatitis C Virus Infectionncbi.nlm.nih.gov
55. [Clinical aspects, course and extrahepatic manifestations of hepatitis C] - PubMedpubmed.ncbi.nlm.nih.gov
56. Clinical Guidelines for the Medical Management of Hepatitis Chealth.ny.gov
57. Hepatitis C Viral RNA Testultalabtests.com
58. Laboratory Tests and Hepatitis C - Viral Hepatitis and Liver Diseasehepatitis.va.gov
59. Clinical Screening and Diagnosis for Hepatitis Ccdc.gov
60. Hepatitis C Virus Diagnostics: The Road to Simplification - PMCpmc.ncbi.nlm.nih.gov
61. Hepatitis C Workup: Approach Considerations, Hepatitis C Antibody Test, Qualitative and Quantitative Assays for HCV RNAemedicine.medscape.com
62. Improving Diagnosis of Hepatitis C Virus Infection Using Hepatitis C Core Antigen Testing in a Resource-Poor Settingncbi.nlm.nih.gov
63. Correlation of liver imaging and transient elastography among patients with hepatitis C at a safety net hospital - PMCpmc.ncbi.nlm.nih.gov
64. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers - PubMedpubmed.ncbi.nlm.nih.gov
65. Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis Cncbi.nlm.nih.gov
66. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection - PubMedpubmed.ncbi.nlm.nih.gov
67. When and in Whom to Initiate HCV Therapyhcvguidelines.org
68. Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapyhcvguidelines.org
69. © Hepatitis C Online PDF created August 18, 2026, 3:57 pmhepatitisc.uw.edu
70. Hepatitis C Virus Test'With Confirmationquesthealth.com
71. Clinical Care of Hepatitis Ccdc.gov
72. Accuracy of noninvasive methods for the diagnosis of liver fibrosis in children with chronic viral hepatitisncbi.nlm.nih.gov
73. Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis Cwjgnet.com
74. Assessing the consistency of liver fibrosis results obtained through biopsy and transient elastography in patients suffering from chronic hepatitis C - PubMedpubmed.ncbi.nlm.nih.gov
75. Chronic Hepatitis C in the Direct-Acting Antivirals Era: Carcinogenesis and Clinical Implications - PMCpmc.ncbi.nlm.nih.gov
76. Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection - PMCpmc.ncbi.nlm.nih.gov
77. A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)ncbi.nlm.nih.gov
78. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis - eClinicalMedicinethelancet.com
79. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwannature.com
80. A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs) - PMCpmc.ncbi.nlm.nih.gov
81. Treatment of Chronic Hepatitis C Virus Infection in Adults - Clinical Guidelines Programhivguidelines.org
82. Recent Advances in the Epidemiology, Screening, and Management of Hepatitis C Virus Infection in Pregnancy - PMCpmc.ncbi.nlm.nih.gov
83. Hepatitis C in pregnancy - PMC - NIHpmc.ncbi.nlm.nih.gov
84. Sustained Virological Response After Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Individuals With and Without Decompensated Liver Cirrhosis: A One-Year Follow-Up Studyncbi.nlm.nih.gov
85. Mathematical modeling of hepatitis C virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies - PMCpmc.ncbi.nlm.nih.gov
86. Viral Hepatitis Among People Who Use or Inject Drugscdc.gov
87. Treatment of HCV in persons who inject drugs: Treatment as preventionjournals.lww.com
88. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsncbi.nlm.nih.gov
89. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)ncbi.nlm.nih.gov
90. Impact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure - PMCpmc.ncbi.nlm.nih.gov
91. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis - ScienceDirectsciencedirect.com
92. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden - PMCpmc.ncbi.nlm.nih.gov
93. Prevention and Treatment of Hepatitis C in Injection Drug Users - PMCpmc.ncbi.nlm.nih.gov
94. Global hepatitis report 2026who.int
95. Global hepatitis report 2024globalhep.org
96. Hepatitiswho.int
97. The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysisbrieflands.com
98. WHO calls for stepped up action to eliminate viral hepatitisnews.un.org
99. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes - PMCpmc.ncbi.nlm.nih.gov
100. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data - PMCpmc.ncbi.nlm.nih.gov
101. Global Viral Hepatitiscdc.gov
102. Systematic overview of hepatitis C infection in the Middle East and North Africawjgnet.com
103. Data & profilesglobalhep.org
104. Global Progress Toward WHO 2030 Hepatitis C Elimination Targetshcplive.com
105. Efforts to eliminate hepatitis delivers gains but more action needed to meet 2030 targetswho.int
106. Elimination of hepatitis by 2030who.int
107. Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Eliminationncbi.nlm.nih.gov
108. Progress on global hepatitis elimination targets - PMC - NIHpmc.ncbi.nlm.nih.gov
109. How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020 to 2023 - PMCpmc.ncbi.nlm.nih.gov
110. Direct-acting antivirals and chronic hepatitis C: towards eliminationoaepublish.com
111. Pathways to ensure universal and affordable access to hepatitis C treatmentncbi.nlm.nih.gov
112. Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countriesacademic.oup.com
113. Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programsjamanetwork.com
114. Hepatitis C microelimination among people living with HIV in Taiwanncbi.nlm.nih.gov
115. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicagoncbi.nlm.nih.gov
116. Challenges in coverage of future hepatitis C vaccines: Review and potential solutions - ScienceDirectsciencedirect.com
117. Update on Hepatitis C Vaccine: Results and Challengesncbi.nlm.nih.gov
118. Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies - PMCpmc.ncbi.nlm.nih.gov
119. Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustionncbi.nlm.nih.gov
120. Liver Organoid and T Cell Coculture Models Cytotoxic T Cell Responses against Hepatitis C Virusbiorxiv.org
121. Vaccination at the forefront of the fight against hepatitis B and C - PMCpmc.ncbi.nlm.nih.gov
122. Vaccine‐induced hepatitis C virus‐specific CD8+ T cells do not always helpjournals.lww.com
123. Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistenceelsevier.es
124. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Upncbi.nlm.nih.gov
125. Modeling of randomized hepatitis C vaccine trials: Bridging the gap between controlled human infection models and real-word testingacademic.oup.com
126. Full article: Current and future prophylactic vaccines for hepatitis C virustandfonline.com
127. A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)clinicaltrials.gov
128. Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Reviewacademic.oup.com
129. Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection - PubMedpubmed.ncbi.nlm.nih.gov
130. New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradicationncbi.nlm.nih.gov
131. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C - PubMedpubmed.ncbi.nlm.nih.gov
132. Editorial commentary: sustained virologic response for patients with hepatitis C-related cirrhosis: a major milestone, but not quite a cure - PubMedpubmed.ncbi.nlm.nih.gov
133. Hepatocellular Carcinoma Developing in a Patient 29 Years After Achieving Sustained Virologic Response for Hepatitis C With Interferon Therapy: A Case Reportncbi.nlm.nih.gov
134. Development of Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 21 Years after Achieving a Sustained Virological Response to Interferon Therapyncbi.nlm.nih.gov
135. Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patientsncbi.nlm.nih.gov
136. Management of Portal Hypertension - PMC - NIHpmc.ncbi.nlm.nih.gov
137. Portal Hypertension and Related Complications: Diagnosis and Management - Mayo Clinic Proceedingsmayoclinicproceedings.org
138. Update on the Complications and Management of Liver Cirrhosis - PMCpmc.ncbi.nlm.nih.gov
139. Impact of hepatitis C oral therapy in portal hypertension - PMCpmc.ncbi.nlm.nih.gov
140. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy - ScienceDirectsciencedirect.com
141. Frontiersfrontiersin.org
142. History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C - ScienceDirectsciencedirect.com
143. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapylink.springer.com
144. Inhibitors of Hepatitis C virus polymeraseimage-ppubs.uspto.gov
145. Frontiers in the Treatment of Hepatitis C Virus Infection - PMCpmc.ncbi.nlm.nih.gov
146. Sofosbuvir: A New Oral Once-Daily Agent for The Treatment of Hepatitis C Virus Infection - PMCpmc.ncbi.nlm.nih.gov
147. Review Antivirals against HCV infection: the story thus farjidc.org
148. Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectivesncbi.nlm.nih.gov
149. Compound for the treatment of hepatitis Cimage-ppubs.uspto.gov
150. FDA Approves 'Game Changer' Hepatitis C Drug Sofosbuvirmedscape.com
151. Development of sofosbuvir for the treatment of hepatitis C virus infection - Lawitz - 2015 - Annals of the New York Academy of Sciences - Wiley Online Librarynyaspubs.onlinelibrary.wiley.com
152. Ledipasviren.wikipedia.org
153. Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate systembiorxiv.org
154. Hepatitis Awho.int
155. Hepatitis Bwho.int
156. Clinical Overview of Viral Hepatitiscdc.gov
157. Hepatitis Delta Infection: A Clinical Review - PMCpmc.ncbi.nlm.nih.gov
158. Hepatitis delta virus - The Lancetthelancet.com
159. Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)cdn.clinicaltrials.gov
160. The hepatitis delta virus: Replication and pathogenesis - Journal of Hepatologyjournal-of-hepatology.eu
161. How to vaccinate and protect against Hepatitis B and Cwho.int
162. Hepatitis B Foundation: ABCs of Viral Hepatitishepb.org
163. Stigma and hepatitis Cblog.catie.ca
164. People who inject drugs report unique barriers to hepatitis C treatmentcatie.ca
165. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma - ScienceDirectsciencedirect.com
166. Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veinsaidsmap.com
167. ‘Treat my whole person, not just my condition’: qualitative explorations of hepatitis C care delivery preferences among people who inject drugsascpjournal.biomedcentral.com
168. Coproduction of Low-Barrier Hepatitis C Virus and HIV Care for People Who Use Drugs in a Rural Community: Brief Qualitative Reportncbi.nlm.nih.gov
169. Disparity in market prices for hepatitis C virus direct-acting drugs - The Lancet Global Healththelancet.com
170. Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries - ScienceDirectsciencedirect.com
171. Accelerating access to hepatitis C diagnostics and treatment: Overcoming barriers in low- and middle-income countries - Global progress report 2020 - Worldreliefweb.int
172. Chronic hepatitis C elimination prison initiative: HCV‐intensive test and treat, a whole prisoner population HCV test‐and‐treat program in England - PMCpmc.ncbi.nlm.nih.gov
173. The Efficacy of On-Site Integration Screening and Microelimination Programs for Chronic Hepatitis C in a Detection Center: A Comparison of the Treatment Outcomes and Characteristics of Incarcerated Patients and Outpatientsncbi.nlm.nih.gov
174. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals eraharmreductionjournal.biomedcentral.com
175. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentencesncbi.nlm.nih.gov
176. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidatepnas.org
177. Epitope-focused immunogens targeting the hepatitis C virus glycoproteins induce broadly neutralizing antibodiesncbi.nlm.nih.gov
178. Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearancejournals.plos.org
179. Frontiersfrontiersin.org
180. Improving Hepatocellular Carcinoma Surveillance Outcomes in Patients with Cirrhosis after Hepatitis C Cure: A Modelling Study - PMCpmc.ncbi.nlm.nih.gov
181. Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines - PMCpmc.ncbi.nlm.nih.gov
182. Nomogram Predicts Long-Term Liver Cancer Risk After Hepatitis C Cureemjreviews.com
183. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease - Journal of Hepatologyjournal-of-hepatology.eu
184. Residual risks of liver cancer persist after hepatitis C cure, finds studymedicalxpress.com
185. Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C study - ScienceDirectsciencedirect.com
186. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugsdx.doi.org
187. Hepatitis C reinfection rates low after successful treatment in people who inject drugseatg.org
188. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysisncbi.nlm.nih.gov
189. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland - PubMedpubmed.ncbi.nlm.nih.gov